The main goal of this paper was to investigate a new potential therapy for COVID-19 by clarifying the effect of HIVC on the prognosis of patients with COVID-19, especially on respiratory function assessed by ventilation-free days. The mechanism of COVID-19 is related to cytokine storms and subsequent immunogenic damage, especially damage to the endothelium and alveolar membrane. Vitamin C (VC), also known as L-ascorbic acid, has been shown to have antimicrobial and immunomodulatory properties. A high dose of intravenous VC (HIVC) was proven to block several key components of cytokine storms, and HIVC has been proven to be safe and therapeutic in critical care medicine, primarily as an adjunct to the treatment of septic shock and multiple organ failure, where it has been shown to improve outcomes and reduce mortality in clinical trials conducted on patients with bacterial-induced sepsis and acute respiratory distress syndrome (ARDS). Compared with these therapies, HIVC has great advantages in terms of stability, availability, safety and cost. Therefore, this trial is highly meaningful as it could potentially save lives at a low price. HIVC is expected to improve pulmonary function and reduce mortality for patients with COVID-19.
